在化疗期间症状管理eRAPID电子健康干预的成本效益
Bryony Dawkins1, Kate Absolom2,3, Jenny Hewison3
1Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom.
JCO oncology practice
|January 24, 2024
概括
电子患者自我报告不良事件:患者信息和建议 (eRAPID) 系统显示了在癌症护理中在线症状监测的潜在成本效益. 这种电子健康干预可能对接受辅助全身治疗的早期癌症患者特别有益.
科学领域:
- 医疗信息学 医疗信息学
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
背景情况:
- 在线症状监测系统可以改善癌症患者的护理.
- 电子患者自我报告不良事件:患者信息和建议 (eRAPID) 系统以前被证明可以增强症状控制和患者的自我有效性.
- 评估这些电子卫生干预措施的成本效益对于医疗保健系统整合至关重要.
研究的目的:
- 评估eRAPID电子卫生干预措施的成本效益,与接受全身治疗的癌症患者的通常护理相比.
- 从医疗保健提供者和社会角度分析成本和质量调整寿命年 (QALYs).
- 探索潜在的长期影响和成本效益的子组变化.
主要方法:
- 与随机对照试验一起进行了嵌入式经济评估.
- 在18周的时间内比较了成本和QALY.
- 增量成本效益比率 (ICER) 通过引导和灵敏度分析来计算和分析;12个月后续数据收集了一个子集.
主要成果:
- eRAPID组在18周内显示出更高的QALY收益和更低的成本,尽管在统计学上并不显著.
- eRAPID显示55%-58%的概率比常规护理更具成本效益,患者自付费用更低.
- 在探索性亚组分析中,观察到早期癌症的成本效益,但没有发现转移性疾病的成本效益.
结论:
- 通过eRAPID系统进行在线症状监测,当与常规的癌症护理相结合时,具有潜在的成本效益.
- 这种干预措施对于接受早期癌症辅助全身治疗的患者来说尤其有价值.
- 需要进一步研究长期影响和特定的患者亚组.
相关概念视频
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
291
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
291
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
203
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
203
01:21Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
01:12Hazard Ratio
124
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
124
01:26Endoscopic Procedures V: ERCP
232
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
Patient...
232